JW Pharmaceutical Corp (001065) - Net Assets
Based on the latest financial reports, JW Pharmaceutical Corp (001065) has net assets worth ₩354.10 Billion KRW (≈ $239.97 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩611.56 Billion ≈ $414.44 Million USD) and total liabilities (₩257.46 Billion ≈ $174.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 001065 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩354.10 Billion |
| % of Total Assets | 57.9% |
| Annual Growth Rate | 4.12% |
| 5-Year Change | 58.81% |
| 10-Year Change | 46.17% |
| Growth Volatility | 13.71 |
JW Pharmaceutical Corp - Net Assets Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's net assets have evolved over time, based on quarterly financial data. Check 001065 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual net assets of JW Pharmaceutical Corp from 2014 to 2024. For live valuation and market cap data, see JW Pharmaceutical Corp stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩329.49 Billion ≈ $223.29 Million |
+24.13% |
| 2023-12-31 | ₩265.44 Billion ≈ $179.89 Million |
+17.58% |
| 2022-12-31 | ₩225.76 Billion ≈ $152.99 Million |
+19.74% |
| 2021-12-31 | ₩188.54 Billion ≈ $127.77 Million |
-9.12% |
| 2020-12-31 | ₩207.47 Billion ≈ $140.60 Million |
-9.83% |
| 2019-12-31 | ₩230.09 Billion ≈ $155.93 Million |
-11.54% |
| 2018-12-31 | ₩260.11 Billion ≈ $176.27 Million |
-3.94% |
| 2017-12-31 | ₩270.78 Billion ≈ $183.50 Million |
-2.00% |
| 2016-12-31 | ₩276.31 Billion ≈ $187.25 Million |
+22.58% |
| 2015-12-31 | ₩225.41 Billion ≈ $152.75 Million |
+2.45% |
| 2014-12-31 | ₩220.02 Billion ≈ $149.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to JW Pharmaceutical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 200.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩164.12 Billion | 49.81% |
| Other Components | ₩165.36 Billion | 50.19% |
| Total Equity | ₩329.49 Billion | 100.00% |
JW Pharmaceutical Corp Competitors by Market Cap
The table below lists competitors of JW Pharmaceutical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Better Home & Finance Holding Company
NASDAQ:BETR
|
$285.41 Million |
|
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
|
$285.53 Million |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
$285.54 Million |
|
Prenetics Global Ltd
NASDAQ:PRE
|
$285.74 Million |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
$285.26 Million |
|
Nongshim Holdi
KO:072710
|
$285.07 Million |
|
First Western Financial Inc
NASDAQ:MYFW
|
$285.06 Million |
|
Qingdao Daneng Environmental Protection Equipment Co Ltd
SHG:688501
|
$285.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JW Pharmaceutical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 265,440,455,810 to 329,486,740,930, a change of 64,046,285,120 (24.1%).
- Net income of 65,040,120,870 contributed positively to equity growth.
- Dividend payments of 9,665,252,800 reduced retained earnings.
- Share repurchases of 750,415,400 reduced equity.
- Other factors increased equity by 9,421,832,450.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩65.04 Billion | +19.74% |
| Dividends Paid | ₩9.67 Billion | -2.93% |
| Share Repurchases | ₩750.42 Million | -0.23% |
| Other Changes | ₩9.42 Billion | +2.86% |
| Total Change | ₩- | 24.13% |
Book Value vs Market Value Analysis
This analysis compares JW Pharmaceutical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.60x to 1.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩13077.48 | ₩20950.00 | x |
| 2018-12-31 | ₩12533.97 | ₩20950.00 | x |
| 2019-12-31 | ₩11131.31 | ₩20950.00 | x |
| 2020-12-31 | ₩10041.95 | ₩20950.00 | x |
| 2021-12-31 | ₩9182.78 | ₩20950.00 | x |
| 2022-12-31 | ₩10656.13 | ₩20950.00 | x |
| 2023-12-31 | ₩11440.15 | ₩20950.00 | x |
| 2024-12-31 | ₩14205.66 | ₩20950.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JW Pharmaceutical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.74%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.04%
- • Asset Turnover: 1.19x
- • Equity Multiplier: 1.83x
- Recent ROE (19.74%) is above the historical average (2.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -1.09% | -0.57% | 0.70x | 2.73x | ₩-23.97 Billion |
| 2015 | 0.87% | 0.45% | 0.71x | 2.73x | ₩-20.52 Billion |
| 2016 | -3.96% | -2.34% | 0.72x | 2.36x | ₩-38.56 Billion |
| 2017 | -0.27% | -0.15% | 0.80x | 2.33x | ₩-27.82 Billion |
| 2018 | 3.10% | 1.50% | 0.90x | 2.28x | ₩-17.95 Billion |
| 2019 | -10.99% | -4.94% | 0.89x | 2.49x | ₩-48.28 Billion |
| 2020 | -7.35% | -2.78% | 1.00x | 2.65x | ₩-35.99 Billion |
| 2021 | -0.48% | -0.16% | 0.96x | 3.15x | ₩-21.09 Billion |
| 2022 | 13.27% | 4.66% | 1.09x | 2.61x | ₩7.86 Billion |
| 2023 | 13.94% | 4.94% | 1.16x | 2.43x | ₩10.46 Billion |
| 2024 | 19.74% | 9.04% | 1.19x | 1.83x | ₩32.09 Billion |
Industry Comparison
This section compares JW Pharmaceutical Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $433,534,628,586
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JW Pharmaceutical Corp (001065) | ₩354.10 Billion | -1.09% | 0.73x | $285.31 Million |
| Dongwha Pharm.Co.Ltd (000020) | $378.67 Billion | 5.38% | 0.22x | $92.51 Million |
| Yuhan Corp. (000100) | $1.19 Trillion | 6.67% | 0.18x | $3.74 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 3.48% | 0.32x | $45.29 Million |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $39.54 Million |
| Yuyu Pharma Inc (000225) | $86.87 Billion | 4.63% | 0.56x | $14.55 Million |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $29.03 Million |
| Ildong Holdings Co Ltd (000230) | $345.58 Billion | 3.16% | 1.32x | $48.82 Million |
| Samil Pharm (000520) | $63.55 Billion | 2.11% | 2.02x | $99.13 Million |
| Donga Socio Holdings (000640) | $190.87 Billion | 12.43% | 2.11x | $365.19 Million |
| Jw Pharmac (001060) | $172.48 Billion | 6.75% | 1.99x | $369.05 Million |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more